| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10803997 | Biochimie | 2012 | 16 Pages |
Abstract
⺠Nowadays, many different chromatin-modifying agents (CMAs) have been developed. ⺠CMAs exert anti-cancer effects through multiple molecular mechanisms. ⺠A large number of clinical trials are ongoing with CMAs on several cancer types. ⺠The mechanism by which CMAs provide clinical benefits is not completely understood. ⺠Combining CMAs to standard therapies is a promising future anti-cancer strategy.
Keywords
AZAAMLDNMT inhibitorFDAEpigenetic inhibitorsDNMTiCMML5-AzacytidineCTCLVPATSGCMAHDACMDSDnmtDACHDACiCMLClinical trialsAnti-cancer therapyFood and Drug Administrationmyelodysplastic syndromeCutaneous T-cell lymphomaacute myeloid leukemiaChronic myeloid leukemiachronic myelomonocytic leukemiaHDAC inhibitorValproic acidTumor suppressor gene
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biochemistry
Authors
Carole Seidel, Cristina Florean, Michael Schnekenburger, Mario Dicato, Marc Diederich,